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Randomized Comparison of
Percutaneous Coronary Intervention With
Coronary Artery Bypass Grafting in Diabetic Patients
1-Year Results of the CARDia (Coronary Artery Revascularization in Diabetes) Trial
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Gianni Angelini, MD, MCH, Adam de Belder, MBBS, MD,¶ Keith G. Oldroyd, MBCHB, MD,#
Marcus Flather, MBBS,†** Michael Roughton, MSC,** Petros Nihoyannopoulos, MD,†
Jens Peder Bagger, MBBS, DSC,† Kenneth Morgan, MBCHB, BSC,† Kevin J. Beatt, MBBS, PHD††
London, Norwich, Middlesbrough, Bristol, and Brighton, England; and Glasgow, Scotland
Objectives The purpose of this study was to compare the safety and efficacy of percutaneous coronary intervention (PCI)
with stenting against coronary artery bypass grafting (CABG) in patients with diabetes and symptomatic mul-
tivessel coronary artery disease.
Background CABG is the established method of revascularization in patients with diabetes and multivessel coronary disease,
but with advances in PCI, there is uncertainty whether CABG remains the preferred method of revascularization.
Methods The primary outcome was a composite of all-cause mortality, myocardial infarction (MI), and stroke, and the
main secondary outcome included the addition of repeat revascularization to the primary outcome events. A
total of 510 diabetic patients with multivessel or complex single-vessel coronary disease from 24 centers were
randomized to PCI plus stenting (and routine abciximab) or CABG. The primary comparison used a noninferiority
method with the upper boundary of the 95% confidence interval (CI) not to exceed 1.3 to declare PCI noninfe-
rior. Bare-metal stents were used initially, but a switch to Cypher (sirolimus drug-eluting) stents (Cordis, Johnson
& Johnson, Bridgewater, New Jersey) was made when these became available.
Results At 1 year of follow-up, the composite rate of death, MI, and stroke was 10.5% in the CABG group and 13.0% in
the PCI group (hazard ratio [HR]: 1.25, 95% CI: 0.75 to 2.09; p  0.39), all-cause mortality rates were 3.2% and
3.2%, and the rates of death, MI, stroke, or repeat revascularization were 11.3% and 19.3% (HR: 1.77, 95% CI:
1.11 to 2.82; p  0.02), respectively. When the patients who underwent CABG were compared with the subset
of patients who received drug-eluting stents (69% of patients), the primary outcome rates were 12.4% and
11.6% (HR: 0.93, 95% CI: 0.51 to 1.71; p  0.82), respectively.
Conclusions The CARDia (Coronary Artery Revascularization in Diabetes) trial is the first randomized trial of coronary revascu-
larization in diabetic patients, but the 1-year results did not show that PCI is noninferior to CABG. However, the
CARDia trial did show that multivessel PCI is feasible in patients with diabetes, but longer-term follow-up and
data from other trials will be needed to provide a more precise comparison of the efficacy of these 2 revascular-
ization strategies. (The Coronary Artery Revascularisation in Diabetes trial; ISRCTN19872154) (J Am Coll
Cardiol 2010;55:432–40) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.014s
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February 2, 2010:432–40 Coronary Revascularization in Diabetic Patientsiabetic patients make up at least one-fourth of all patients
eferred for revascularization (1). Their risk of complications
rom all types of revascularization procedures are higher
han that in patients without diabetes, and their long-term
rognosis is worse (2–8). The pattern of coronary artery
isease in diabetic patients is often complex, with multiple
esions and widespread disease (9), making effective revas-
ularization difficult.
The BARI (Bypass Angioplasty Revascularization Inves-
igation) compared percutaneous coronary intervention
PCI) with coronary artery bypass grafting (CABG) in
atients with multivessel disease, with a primary end point
f mortality at 5 years (10). The analysis of the subset of 353
iabetic patients showed that after 5 years of follow-up,
atients initially treated with PCI had double the mortality
f those randomized to CABG (11). CABG was already
stablished as the standard revascularization strategy in
ondiabetic patients with left main stem coronary artery
isease or 3-vessel coronary disease and impaired LV
unction, and the BARI subgroup results led to this being
xtended to all patients with diabetes and multivessel
isease. However, the BARI was conducted before bare-
etal stents (BMS) and glycoprotein IIb/IIIa inhibitors
ere available. In addition, PCI has evolved further with the
ntroduction of drug-eluting stents (DES) and new oral
ntiplatelet strategies (12–15) There have also been devel-
pments in surgery, including increased arterial revascular-
zation and off-pump techniques, but their impact on
utcome has been less dramatic (16–18). In the context of
he continuing refinement in treatment strategies and an
ncrease in the number of diabetic patients requiring revas-
ularization, there is a need to continually assess the role of
ontemporary PCI compared with CABG. Accordingly, the
ARDia (Coronary Artery Revascularization in Diabetes)
rial was undertaken to compare PCI plus stenting with
ABG in patients with diabetes and multivessel coronary
rtery disease (19).
ethods
he trial design and study protocol were described previ-
usly (19). In brief, patients were considered eligible if they
ad diabetes and either multivessel coronary disease or
omplex single-vessel disease (ostial or proximal left anterior
escending artery disease) and were recommended to have
oronary revascularization on clinical grounds. After review
f each case by an experienced interventional cardiologist
nd cardiac surgeon, there had to be agreement that there
as reasonable equipoise in the risks and benefits of PCI
nd CABG before a patient could be randomized. The
xclusion criteria were the inability to consent, age older
han 80 years, previous revascularization, left main stem
isease, cardiogenic shock, recent ST-segment elevation
yocardial infarction (MI) (within 6 weeks), known ejec-
ion fraction 20%, and contraindications to antiplatelet
herapy. National and institutional ethical approval was obtained for all 24 participating
enters in the United Kingdom
n  22) and Ireland (n  2)
Online Appendix). All patients
ave written informed consent
efore randomization. Random-
zation was undertaken, by either
local secure computer-based
ystem or telephone contact with
he coordinating center stratify-
ng for urgency of intervention
acute/elective), sex, and number
f diseased vessels (3/3). Con-
rmation of eligibility criteria
as required before release of
andomization allocation. Center-
pecific randomization was undertaken with stratification
ccording to sex, number of diseased vessels, and whether
he procedure was urgent or elective. Operators in both
reatment arms were encouraged to perform as complete a
evascularization as possible. Staged procedures were al-
owed and included as part of the index revascularization if
he operator decided this before the end of the initial
rocedure. Contemporary techniques, such as arterial revas-
ularization and off-pump procedures, were encouraged in
atients randomized to CABG. The PCI strategy included
he unrestricted use of stents and routine administration of
bciximab. The trial was started using BMS, but when they
ecame available, patients received DES (Cypher stents,
ordis, Johnson & Johnson, Bridgewater, New Jersey). The
rotocol recommendation for clopidogrel use after PCI was
to 3 months after BMS placement and 12 months after
ES placement. The primary end point was a composite of
eath, MI, and stroke assessed at 1 year after randomization
ith a major secondary end point of repeat revascularization
lso assessed at 1 year. With the advent of troponin, the
efinition of MI was amended, and this together with the
efinitions of the trial end points are summarized (Online
ppendix). The reporting of a serious adverse event was
ased on notification by the local investigator and in the case
f MI did not depend on routine biomarker assessment
ost-procedure.
utcomes and follow-up. All major events including death,
I, stroke, bleeding, and repeat revascularization were re-
iewed by the Critical Events Adjudication Committee, which
onsisted of cardiologists and surgeons who were blinded to
reatment allocation. There were 2 adjudicators for each event,
ith a third used if required. An independent Data and Safety
onitoring Board comprising 2 cardiologists and 1 surgeon
eviewed trial data according to protocol.
tatistical methods. All analyses were performed using the
ntent-to-treat principle. The primary outcome was the
omposite of all-cause mortality, nonfatal MI, and nonfatal
troke at 1 year (time to first event). Additional outcomes of
nterest were the individual elements of the composite
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
MACCE  major adverse
coronary and cerebral
events
MI  myocardial infarction
PCI  percutaneous
coronary interventionutcome, repeat revascularization, bleeding, angina classifi-
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Coronary Revascularization in Diabetic Patients February 2, 2010:432–40ation, and the composite of the primary outcome and
epeat revascularization (major adverse coronary and cere-
ral events [MACCE]). Timing of follow-up was taken
rom the date of randomization, with all patients being
ensored at their last observed follow-up time, or 365 days
f their last observed follow-up time was 1 year. A Cox
roportional hazards model was used to compare the sur-
ival times in the 2 treatment arms, and the survival
istributions were constructed using the Kaplan-Meier
ethod. Results of the survival analysis are presented as
nadjusted hazard ratio (HR) and 95% confidence interval
CI). Variables are summarized using mean (SD) or number
%), as appropriate. Comparisons of continuous variables
ere made using t tests, and the chi-square test was used to
ompare categorical variables. All analyses were performed
sing Stata 10.1 (StataCorp, College Station, Texas), and a
value 0.05 was considered to be statistically significant.
re-specified subgroups included 3-vessel/2-vessel disease,
MS or DES, insulin/no insulin treatment, sex, age
younger than 65/65 years and older). For the BMS/DES
ubgroup, PCI patients were compared with concurrent
ABG controls using the date that the DES was first
Figure 1 Patient Enrollment and Follow-Up
*These patients are included in the 1-year follow-up. CABG  coronary artery bypantroduced as the cut point (excluding the few patients who oeceived only BMS after this date). The p values for
nteraction in these subgroups (i.e., whether there seems to
e a difference in treatment effect in the strata of the
ubgroup) are provided.
ample size estimate. CABG has historically been as-
umed to be superior to PCI in patients with diabetes and
ultivessel disease. The sample size was calculated at 600
atients, based on event rates in the ARTS (Arterial
evascularization Therapy Study) (6), the meta-analysis of
he EPIC (Evaluation of 7E3 for the Prevention of Isch-
mic Complications), EPILOG (Evaluation in PCTA to
mprove the Long-Term Outcome With Abciximab GP
Ib/IIIa), and EPISTENT (Evaluation of Platelet IIb/IIIa
nhibitor for Stenting) trials (20) as well as the ability to
nroll this number over approximately 3 years. We used an
xploratory noninferiority design model (21). The most
avorable assumption was that the composite of death, MI,
nd stroke would occur at a rate of 9.0% in the PCI arm and
t 12.5% in the surgical arm, suggesting that an odds ratio
f 0.69 in favor of PCI (with upper CI boundary of 1.3)
ould allow us to declare PCI as noninferior. We recog-
ized that the study could be underpowered for clinical
fting; PCI  percutaneous coronary intervention.ss grautcomes, but would have reasonable power (approximately
8
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w
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February 2, 2010:432–40 Coronary Revascularization in Diabetic Patients0% power at alpha  0.05) to detect differences in the
omposite of death, stroke, MI, or repeat revascularization,
hich is the MACCE outcome used in the ARTS 1 (6).
hus, the sample size was a pragmatic one based on
Baseline Clinical Characteristics of CARDia TriaTable 1 Baseline Clinical Characteristics of
Variable
Age (yrs), mean (SD)
Male, n (%)
Systolic blood pressure (mm Hg), mean (SD)
Diastolic blood pressure (mm Hg), mean (SD)
Heart rate (beats/min), mean (SD)
Body mass index (kg/m2), mean (SD)
Ethnicity, n (%)
White
Asian
Black
Other
Admission type, n (%)
Acute
Elective
Diabetes status
Type 1, n (%)
Noninsulin treated, n (%)
Insulin treated, n (%)
Years with diabetes, mean (SD)
Smoking status, n (%)
Nonsmoker
Ex-smoker
Smoker
Unknown
Diseased vessels, n (%)
3-vessel disease
2-vessel disease
Bifurcation
Proximal LAD
Hypertension, n (%)
Hyperlipidemia, n (%)
History of renal impairment, n (%)
Peripheral vascular disease, n (%)
COPD, n (%)
Cerebrovascular disease history (stroke or TIA), n (%)
Left ventricular function, n (%)*
Normal or good
Mild impairment
Moderate impairment
Severe impairment
Ejection fraction (%), mean (SD)
Creatinine (mol/l), mean (SD)
Cholesterol (mmol/l), mean (SD)
LDL (mmol/l), mean (SD)
HDL (mmol/l), mean (SD)
Triglyceride (mmol/l), mean (SD)
*Assessed using a qualitative scale from the angiogram.
CABG coronary artery bypass grafting; CARDia Coronary Artery R
HDL  high-density lipoprotein; LAD  left anterior descending artery
TIA  transient ischemic attack.rojected enrollment rates. Tesults
he trial enrolled 510 patients (254 were randomized to
ABG and 256 to PCI) from January 2002 to May 2007.
ientsDia Trial Patients
Total
n  510)
CABG
(n  254)
PCI
(n  256)
510 63.6 (9.1) 64.3 (8.5)
509 197 (77.9) 181 (70.7)
434 137.3 (18.7) 136.7 (20.8)
434 73.3 (12.0) 73.6 (10.6)
431 69.9 (13.2) 68.7 (12.9)
486 29.4 (5.3) 29.2 (4.9)
505
181 (72.4) 171 (67.1)
52 (20.1) 66 (25.9)
6 (2.4) 6 (2.4)
11 (4.4) 12 (4.7)
510
60 (23.6) 55 (21.5)
194 (76.4) 201 (78.5)
510
17 (6.7) 8 (3.1)
155 (60.9) 168 (65.5)
99 (39.1) 88 (36.5)
477 10.4 (9.6) 10.1 (9.6)
510
161 (63.4) 162 (63.3)
15 (5.9) 12 (4.7)
59 (23.2) 63 (24.6)
19 (7.5) (7.4)
510
149 (59.7) 166 (64.8)
88 (34.7) 72 (28.1)
5 (2.0) 2 (0.8)
12 (4.7) 16 (6.3)
508 203 (80.6) 196 (76.6)
507 220 (87.3) 237 (92.9)
508 10 (4.0) 14 (5.5)
508 13 (5.2) 6 (2.4)
446 24 (9.5) 24 (9.4)
508 12 (5.6) 8 (3.5)
329
106 (59.3) 98 (55.4)
37 (24.3) 43 (24.3)
23 (15.1) 34 (19.2)
2 (1.3) 2 (1.1)
256 60.0 (12.7) 59.1 (14.4)
431 107.0 (70.7) 104.2 (50.2)
372 3.85 (0.94) 4.05 (1.05)
244 1.94 (0.69) 2.13 (0.84)
292 1.17 (0.57) 1.17 (0.49)
320 1.88 (1.11) 1.84 (1.04)
larization in Diabetes; COPD chronic obstructive pulmonary disease;
low-density lipoprotein; PCI  percutaneous coronary intervention;l PatCAR
(
evascu
; LDL he median follow-up was 365 days. In the CABG group,
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Coronary Revascularization in Diabetic Patients February 2, 2010:432–4030 of 254 patients (91%) actually underwent CABG, with
patient dying before the operation and 14 crossing over to
CI. In the PCI group, 253 of 256 patients (99%) actually
nderwent PCI, and 1 patient crossed over to CABG (Fig.
). Baseline clinical characteristics were well matched, and
he number of diseased vessels, baseline creatinine, and left
entricular function were also similar between the 2 groups
Table 1). Thirty-eight percent of patients were treated with
nsulin, and 5% of all patients had type 1 diabetes. The
uration of diabetes before randomization for each group
as 10 years, and the baseline glycosylated hemoglobin was
.9% in both groups. It was a protocol requirement that all
atients in both groups had aggressive diabetic control
ost-randomization with a target glycosylated hemoglobin
f 7%. However, this target was not achieved, and it
emained 7.9% in the CABG group and 7.7% in the PCI
roup at the 1 year follow-up (p  0.086).
The time from randomization to procedure was a median
f 64 days for CABG and 38 days for PCI (p 0.001). This
eflected the relatively long waiting times in the United
ingdom during the course of this study. The time spent in
ospital was a median of 9 days for surgery and 1 day for
ngioplasty (p  0.001). In the PCI group before the
rocedure, 100% of patients took aspirin, 95% clopidogrel,
nd 95% abciximab. Sixty-five percent of patients had
-vessel disease, of whom 88% had complete revasculariza-
ion and only 2.6% had staged procedures. On average, 3.6
tents (a mean total stent length of 71 mm) were implanted
er patient. Cypher stents were used in 69% of patients and
MS in 31%. Fifteen patients received both DES and
MS and were included in the DES subgroup. In the
ABG group, 60% of patients had 3-vessel disease, of
hom 90% underwent complete revascularization. On av-
rage, 2.9 grafts were used per patient. Ninety-four percent
f patients underwent a left internal mammary artery graft
nd 17% at least 2 arterial grafts, and 31% underwent
ff-pump surgery.
The combined rate of death, MI, and stroke in the
ABG group was 10.5% compared with 13.0% in the PCI
roup (HR: 1.25, 95% CI: 0.75 to 2.09) (Fig. 2A). The
oninferiority margin of 1.3 was exceeded by the upper limit
f the CI for the primary end point, indicating that our
esults could not demonstrate that PCI is noninferior to
ABG. Subsequent comparisons are all provided using
onventional comparative methods. The all-cause mortality
ate in the CABG group was 3.2% and 3.2% in the PCI
roup (p  0.97; HR: 0.98, 95% CI: 0.37 to 2.61) with
epeat revascularization rates of 2.0% and 11.8% (p 0.001,
R: 5.31, 95% CI: 2.0 to 14.11), respectively. The com-
osite of MACCE combining repeat revascularization with
he primary end point was 11.3 versus 19.3%, (p  0.016;
R: 1.77; 95% CI: 1.11 to 2.82) in the CABG and PCI
roups, respectively (Fig. 2B). The occurrence rate of
hrombolysis In Myocardial Infarction (TIMI) major
leeding at 1 year in the CABG group compared with the
CI group was 6.1% versus 1.2% (p  0.009; HR: 0.19, 05% CI: 0.06 to 0.67), respectively. Peri-procedural MI
ates were similar in the 2 groups, but the rate of late MI
ccurring 7 days after the index revascularization proce-
ure was higher in the PCI arm (p  0.016) (Table 2).
Initially, BMS were used in the CARDia trial, but
ubsequently DES became available and were used rou-
inely. We compared outcomes for PCI patients under-
oing DES placement with CABG patients enrolled
uring the same time period (and the same for PCI
atients undergoing BMS placement). The rates of
eath, MI, or stroke in this subgroup of CABG versus
ES patients (n  350; 69% of the total sample) were
2.4% versus 11.6%, respectively (HR: 0.93; 95% CI:
Figure 2
Primary End Point Event-Free
Survival CABG Versus PCI and MACCE
Event-Free Survival CABG Versus PCI
Shown are the 1-year Kaplan-Meier event-free survival curves for CABG (blue
line) and PCI (orange line) for the primary outcome of death, myocardial infarc-
tion (MI), or stroke (A) and death, MI, stroke, or repeat revascularization
(revasc) (major adverse coronary and cerebral events [MACCE]) (B). Hazard
ratios and 95% confidence intervals for these comparisons are provided in
Table 2. Abbreviations as in Figure 1..51 to 1.71), and for CABG versus BMS patients (n 
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February 2, 2010:432–40 Coronary Revascularization in Diabetic Patients52), they were 5.7% versus 15.9% (HR: 2.99; 95% CI: 0.97 to
.16; test for interaction p  0.076) (Table 3, Fig. 3).
ACCE rates were 12.9% versus 18.0% (p  0.14) in the
ABG versus DES patients (Table 3). In the subgroup of
atients with 3-vessel disease, which accounted for approxi-
ately 60% of patients, the composite of death, MI, and stroke
ccurred in 11.0% versus 15.2%, and for 2-vessel disease
atients, the rates were 9.8% versus 8.9%, in CABG and PCI
roups respectively (interaction p  0.4). Full data for the 5
ubgroups tested for the primary outcome and for MACCE
re shown in Table 3 and Figure 3.
ajor End Points at 1 YearTable 2 Major End Points at 1 Year
Adjudicated Events Post-Randomization
Death
Nonfatal MI (total)
Periprocedural MI
Late MI*
Nonfatal stroke
Composite outcome of death, nonfatal MI, and nonfatal stroke at 1 year:
primary outcome
Further revascularization at 1 year
Composite outcome of death, nonfatal MI, nonfatal stroke, and repeat
revascularization at 1 year: secondary outcome
TIMI major bleed
alues are n (%). *Late MI defined as occurring 7 days after index revascularization procedure.
CI  confidence interval; HR  hazard ratio; MI  myocardial infarction; TIMI  Thrombolysis I
utcomes in Subgroups of InterestTable 3 Outcomes in Subgroups of Interest
CABG
Patients n (%) Patient
Death, MI, stroke at 1 yr
2-vessel disease 102 10 (9.8) 90
3-vessel disease 146 16 (11.0) 164
BMS group 70 4 (5.7) 82
DES group 178 22 (12.4) 172
No insulin 151 16 (10.6) 161
Insulin 97 10 (10.3) 92
Female 56 4 (7.1) 74
Male 192 22 (11.5) 180
Age 65 yrs 123 14 (11.4) 119
Age 65 yrs 125 12 (9.6) 135
Death, MI, stroke, repeat revascularization (MACCE)
2-vessel disease 102 10 (9.8) 90
3-vessel disease 146 18 (12.3) 164
BMS group 70 5 (7.1) 82
DES group 178 23 (12.9) 172
No insulin 151 18 (11.9) 161
Insulin 97 10 (10.3) 92
Female 56 5 (8.9) 74
Male 192 23 (12.0) 180
Age 65 yrs 123 14 (11.4) 119
Age 65 yrs 125 14 (11.2) 135MS  bare-metal stent(s); DES  drug-eluting stent(s); MACCE  major adverse coronary and cerebralMedication use at 1 year showed some imbalances,
ith clopidogrel use being higher in the PCI group, as
ould be expected, whereas more patients were taking
nsulin in the CABG group at 1 year. Statins and aspirin
ere used in approximately 85% in both groups at 1 year
Table 4). A comparison of CABG and PCI at baseline
howed that Canadian Cardiovascular Society class was
imilar in both groups (p  0.719). After 1 year,
ymptoms had improved in both groups, but patients
andomized to CABG had significantly less angina (p 
.001) (Table 4).
BG
248)
PCI
(n  254)
PCI vs. CABG
HR (95% CI) p Value
(3.2) 8 (3.2) 0.98 (0.37–2.61) 0.97
(5.7) 25 (9.8) 1.77 (0.92–3.40) 0.088
(4.4) 12 (4.7) 1.08 (0.47–2.44) 0.819
(1.2) 14 (5.5) 4.64 (1.33–16.16) 0.016
(2.8) 1 (0.4) 0.14 (0.02–1.14) 0.066
(10.5) 33 (13.0) 1.25 (0.75–2.09) 0.393
(2.0) 30 (11.8) 6.18 (2.40–15.94) 0.001
(11.3) 49 (19.3) 1.77 (1.11–2.82) 0.016
(6.1) 3 (1.2) 0.19 (0.06–0.67) 0.009
patient in the PCI group had both a periprocedural and a late MI.)
ardial Infarction.
CI
HR 95% CI
Interaction
p Valuen (%)
8 (8.9) 0.9 0.36–2.28 0.419
25 (15.2) 1.42 0.76–2.67
13 (15.9) 2.99 0.97–9.16 0.076
20 (11.6) 0.93 0.51–1.71
17 (10.6) 1.02 0.51–2.01 0.348
16 (17.4) 1.67 0.76–3.67
11 (14.9) 2.13 0.68–6.68 0.289
22 (12.2) 1.07 0.59–1.93
14 (11.8) 1.04 0.49–2.17 0.497
19 (14.1) 1.48 0.72–3.05
13 (14.4) 1.48 0.65–3.38 0.641
36 (22.0) 1.88 1.07–3.31
18 (22.0) 3.42 1.27–9.22 0.131
31 (18.0) 1.41 0.82–2.42
26 (16.2) 1.41 0.77–2.58 0.243
23 (25.0) 2.47 1.18–5.2
15 (20.3) 2.4 0.87–6.61 0.489
34 (18.9) 1.62 0.95–2.74
21 (17.7) 1.58 0.8–3.1 0.662
28 (20.7) 1.94 1.02–3.68CA
(n 
8
14
11
3
7
26
5
28
15P
sevent; other abbreviations as in Tables 1 and 2.
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he CARDia trial is the first prospective randomized trial
o evaluate the safety and efficacy of PCI compared with
hose of CABG in patients with diabetes. There was a
onsignificantly higher rate of the composite of death, MI,
nd stroke (driven by a higher rate of MI) and significantly
igher rates of repeat revascularization in the PCI group.
he pre-specified noninferiority margin was not met.
troke rates showed a trend favoring PCI, and mortality
ates were the same in the 2 groups. The trial provides the
Figure 3 Forest Plot of Death, Myocardial
Infarction, and Stroke in Key Subgroups
Squares represent point estimates for the hazard ratio (HR) and horizontal
lines represent 95% confidence interval (CI). Arrows indicate that the upper
limit of HR goes off the log scale. Also see Table 3. BMS  bare-metal
stent(s); DES  drug-eluting stent(s); other abbreviations as in Figure 1.
edications and CCS Class at Baseline and 1 YearTable 4 Medications and CCS Class at Baseline and 1 Year
CABG Baseline
(n  246)
PCI Baseline
(n  252)
Medications and HbA1c
Aspirin 208 (82.2) 224 (87.5)
Clopidogrel 71 (28.1) 109 (42.8)
Aspirin and clopidogrel 65 (25.7) 101 (39.6)
Statins 134 (53.0) 144 (56.5)
ACE inhibitors 207 (81.8) 223 (87.5)
Oral hypoglycemics 152 (60.1) 167 (65.5)
Insulin 99 (39.1) 93 (36.5)
HbA1c, mean (SD) 7.9 (1.6) 7.9 (1.4)
CCS class
0 38 (15.5) 38 (15.1)
I 165 (67.1) 183 (72.6)
II 27 (11.0) 19 (7.5)
III 12 (4.9) 9 (3.6)
IV 1 (0.4) 1 (0.4)
IVa 3 (1.2) 2 (0.8)
alues are n (%) unless otherwise indicated. There were no significant differences between gro
enominators due to missing data.
ACE  angiotensin-converting enzyme; CCS  Canadian Cardiovascular Society; HbA1c  glycosylatedargest existing dataset of diabetic patients with complex
isease randomized to PCI or CABG.
The event rate in the PCI arm was higher than predicted,
ikely due to the increased complexity of coronary disease in
he CARDia trial compared with previous trials, a trend also
een in the SYNTAX (Synergy Between PCI With Taxus
nd Cardiac Surgery) trial. The SYNTAX trial using the
YNTAX score as a measure of complexity showed that
ncreased complexity has a disproportionately adverse effect
n the outcome of PCI patients compared with CABG
atients (22). This largely unforeseen change in practice will
eed to be taken into consideration when calculating sample
izes for future trials and when applying the result to current
linical practice.
The prevalence of diabetes is increasing, and approxi-
ately 8% of adults in developed countries have diabetes
23). Cardiovascular complications remain the leading cause
f mortality among patients with type 2 diabetes mellitus,
ccounting for as many as 80% of deaths (24,25). Although
ABG is generally considered a more effective revascular-
zation strategy in patients with diabetes, it also carries a
reater morbidity, increased length of hospital stay, and
onger recovery times compared with PCI.
The BARI (subjects recruited from 1988 to 1991) first
ighlighted the difference in mortality rates between CABG
nd PCI in diabetic patients (11). The ARTS (recruited
rom 1996 to 1997) showed mortality rates of 3.1% for
ABG and 6.3% for PCI at 1 year (6). In the CARDia trial,
ortality for the PCI group was 3.2%, which is one-half
hat seen in the ARTS diabetic subgroup, whereas CABG
ortality was the same as in the ARTS at 3.2%. Overall
ates of MI in the PCI group were nonsignificantly higher
han CABG, and this seems to be driven by a significant
CABG at 1 Year
(n  217)
PCI at 1 Year
(n  223)
p Value
CABG vs. PCI at 1 Year
197 (87.2) 191 (83.4) 0.258
23 (10.3) 124 (54.4) 0.001
15 (16.5) 116 (50.9) 0.001
201 (89.3) 191 (83.4) 0.066
135 (60.3) 128 (56.1) 0.374
138 (61.1) 150 (65.5) 0.326
92(40.9) 68(29.8) 0.014
7.9 (1.6) 7.7 (1.4) 0.106
192 (88.5) 159 (71.3) 0.001
16 (7.4) 37 (16.6) (global p value for all
classes of angina)8 (3.7) 21 (9.4)
1 (0.5) 2 (0.9)
0 (0) 3 (1.4)
0 1 (0.5)
baseline. One-year denominators are maximum number available; some groups have smallerups athemoglobin; other abbreviations as in Table 1.
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rocedure. In the ARTS, the rate of revascularization was
2.3% at 1 year in the PCI diabetic subgroup (4.1% for
ABG), but in the CARDia trial, the rate was 11.8% (9.4%
n those receiving DES), although this was still considerably
igher than the CABG revascularization rate of 2.0% (p 
.001) (6). Thus, the improvement over time seems greater
n the patients treated with PCI. These improved outcomes
re despite the fact that patients recruited in the CARDia
rial had more extensive disease. For example, 3-vessel
isease accounted for just 36% and 38% of patients in the
ABG and PCI diabetic subsets, respectively, in the ARTS
ompared with 60% and 65% in the CARDia trial (Table 1).
n average, 3.0 stents were implanted in the ARTS PCI
iabetic subset with an average total stent length per patient
f 52 mm. The respective figures for the CARDia trial were
.6 and 71 mm. The recently reported SYNTAX trial shows
continuation of the trend with figures of 4.6 and 86 mm,
espectively, in the study as a whole (22). In the ARTS, MI
ates at 1 year were 2.1% in the CABG arm, 6.3% in the
CI arm, and 0.6% in the DES arm (26). The rate of MI in
ARDia trial was higher, although this may be related to
he MI definition, which has often varied among trials
27,28).
In contrast to these progressive improvements, a finding
hat has remained largely consistent throughout the land-
ark revascularization trials has been the higher stroke rate
n the CABG arm compared with the PCI arm, particularly
or diabetic patients. In the recent SYNTAX trial, stroke
ates were 2.2% and 0.6% in the CABG and PCI groups,
espectively (22). The higher stroke rate observed in both
he CARDia and SYNTAX trials in the surgical arm needs
o be taken into consideration when deciding which revas-
ularization procedure is preferred in these patients. A
ecent individual patient data meta-analysis of all random-
zed CABG versus PCI trials (including older pre-stent
rials) with a total sample size of 7,812 patients has shown
hat overall mortality rates for a median follow-up of 6 years
ere approximately 16% in both groups, but mortality (even
xcluding the BARI) was significantly lower in diabetic
atients in the CABG group, and there was also a favorable
rend for CABG with older age (29). Because the overall
ARDia trial was underpowered, we cannot make any clear
tatements about the subgroups, even though these are
resented (Table 3, Fig. 3); however, there seemed to be a
rend suggesting that DES may provide a better outcome
han BMS.
tudy limitations. The CARDia trial was underpowered
or the primary composite outcome, but we believe that this
utcome was more meaningful and consistent with other
ajor cardiovascular therapy trials, than the conventional
ACCE outcome, which is driven by repeat revasculariza-
ion. Longer-term follow-up will increase power, as has
een observed in other trials (11,30). None of the CABG
ersus PCI trials have been adequately powered for clinical
utcomes, and even the pooled analysis of all the random- Bzed trials with approximately 7,800 patients has not shown
lear differences in mortality between the 2 strategies (29).
e achieved 85% of the expected sample, which still
epresents the largest study of revascularization in diabetic
atients. The definition and detection of MI in the CARDia
rial can be questioned because central monitoring of mark-
rs of myocardial damage was not performed, but, as
iscussed, there is no consensus on how MI should be
etected in a clinical trial setting, and our approach of
nvestigator-reported events with central adjudication re-
ains valid. The type of stent used changed during the trial
rom BMS to DES, which is a simple reflection of the
ver-changing practice in coronary revascularization, and
ost trials have had changes in practice during the enroll-
ent phase including new balloons, guide catheters, and
tents. Although the CARDia trial was a comparison of 2
evascularization strategies, there may be some patients with
ype 2 diabetes and stable coronary disease who will do
qually well with optimal medical therapy, as recently
llustrated by BARI in type 2 diabetes (31).
onclusions
he 1-year results of the CARDia trial did not demonstrate
he noninferiority of PCI versus CABG for revasculariza-
ion of diabetic patients. However, the results suggest that
here could be greater equipoise between the 2 strategies,
ith the decision to use CABG or PCI being based on
nformation from clinical trials, clinician judgment, and
atient preference. Longer-term follow-up of the CARDia
rial and data from other ongoing trials such as FREEDOM
Future REvascularization Evaluation in Patients with Di-
betes Mellitus: Optimal Management of Multivessel Dis-
ase) (32) will provide further information on optimal
trategies for coronary revascularization in diabetic patients.
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APPENDIX
or a list of participating centers, primary end point definitions, and the
rial committees, please see the online version of this article.
